{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T05:23:55Z","timestamp":1747977835408,"version":"3.41.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","surgonc.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.soc.2025.01.005","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T21:18:14Z","timestamp":1741295894000},"page":"343-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nodal Management in Melanoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Derek","family":"Effiom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.soc.2025.01.005_bib1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3322\/caac.20141","article-title":"Cancers with increasing incidence trends in the United States: 1999 through 2008","volume":"62","author":"Simard","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"3607","key":"10.1016\/j.soc.2025.01.005_bib2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S0140-6736(01)88090-9","article-title":"Abstract of a lecture on melanotic cancerous disease","volume":"140","year":"1892","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.soc.2025.01.005_bib3","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/0002-9610(76)90325-1","article-title":"Analysis of survival and disease control in stage I melanoma of the head and neck","volume":"132","author":"Ames","year":"1976","journal-title":"Am J Surg"},{"issue":"2","key":"10.1016\/j.soc.2025.01.005_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00567362","article-title":"Early metastases in regional lymph nodes and prognosis of malignant melanoma. Histological and clinical examinations in 104 lymphadenectomized patients","volume":"256","author":"Weidner","year":"1976","journal-title":"Arch Dermatol Res (1975)"},{"issue":"12","key":"10.1016\/j.soc.2025.01.005_bib5","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/1097-0142(19901215)66:12<2522::AID-CNCR2820661213>3.0.CO;2-Z","article-title":"The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma","volume":"66","author":"Crowley","year":"1990","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.soc.2025.01.005_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.1988.6.1.163","article-title":"The role of elective lymph node dissection in melanoma: rationale, results, and controversies","volume":"6","author":"Balch","year":"1988","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.soc.2025.01.005_bib7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1056\/NEJM197709222971202","article-title":"Inefficacy of immediate node dissection in stage 1 melanoma of the limbs","volume":"297","author":"Veronesi","year":"1977","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.soc.2025.01.005_bib8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0002-9610(05)81181-X","article-title":"Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection","volume":"164","author":"Beitsch","year":"1992","journal-title":"Am J Surg"},{"issue":"6","key":"10.1016\/j.soc.2025.01.005_bib9","first-page":"600","article-title":"Elective and therapeutic regional lymph node dissection for cutaneous malignant melanoma: experience of the British Columbia Cancer Agency, 1972 to 1981","volume":"35","author":"Carmichael","year":"1992","journal-title":"Can J Surg"},{"issue":"11","key":"10.1016\/j.soc.2025.01.005_bib10","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/1097-0142(19820601)49:11<2420::AID-CNCR2820491133>3.0.CO;2-2","article-title":"Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities","volume":"49","author":"Veronesi","year":"1982","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.soc.2025.01.005_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/1097-0142(19850715)56:2<413::AID-CNCR2820560234>3.0.CO;2-T","article-title":"The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm)","volume":"56","author":"Elder","year":"1985","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.soc.2025.01.005_bib12","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1002\/1097-0142(19830601)51:11<2152::AID-CNCR2820511134>3.0.CO;2-7","article-title":"Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients","volume":"51","author":"Urist","year":"1983","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.soc.2025.01.005_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00000658-197701000-00002","article-title":"Comparison of lymphedema following incontinuity and discontinuity groin dissection","volume":"185","author":"Papachristou","year":"1977","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.soc.2025.01.005_bib15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma","volume":"127","author":"Morton","year":"1992","journal-title":"Arch Surg"},{"issue":"4","key":"10.1016\/j.soc.2025.01.005_bib16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10585-023-10254-2","article-title":"Sentinel lymph nodes in melanoma: necessary as ever for optimal treatment","volume":"41","author":"Faries","year":"2024","journal-title":"Clin Exp Metastasis"},{"issue":"11","key":"10.1016\/j.soc.2025.01.005_bib17","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.2010.33.1884","article-title":"Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis","volume":"29","author":"Valsecchi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2025.01.005_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0039-6060(98)70121-7","article-title":"Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid","volume":"124","author":"Gershenwald","year":"1998","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.soc.2025.01.005_bib19","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.1999.17.3.976","article-title":"Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients","volume":"17","author":"Gershenwald","year":"1999","journal-title":"J Clin Oncol"},{"issue":"9105","key":"10.1016\/j.soc.2025.01.005_bib20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(97)08260-3","article-title":"Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme","volume":"351","author":"Cascinelli","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.soc.2025.01.005_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10434-000-0087-9","article-title":"Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial","volume":"7","author":"Balch","year":"2000","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2025.01.005_bib22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/00000658-198212001-00011","article-title":"A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia","volume":"196","author":"Balch","year":"1982","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.soc.2025.01.005_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00000658-199609000-00002","article-title":"Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger","volume":"224","author":"Balch","year":"1996","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.soc.2025.01.005_bib24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00008390-199506000-00008","article-title":"Elective lymph node dissection in primary malignant melanoma: a matched-pair analysis","volume":"5","author":"Rompel","year":"1995","journal-title":"Melanoma Res"},{"issue":"7","key":"10.1016\/j.soc.2025.01.005_bib25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.soc.2025.01.005_bib26","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.soc.2025.01.005_bib27","first-page":"835","article-title":"Therapeutic value of sentinel lymph node biopsy in patients with melanoma: a randomized clinical trial","volume":"157","year":"2022","journal-title":"JAMA Surgery"},{"issue":"32","key":"10.1016\/j.soc.2025.01.005_bib28","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.18.02306","article-title":"Final analysis of DeCOG-SLT trial: No survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node","volume":"37","author":"Leiter","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.soc.2025.01.005_bib29","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.soc.2025.01.005_bib30","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1245\/s10434-023-14050-w","article-title":"Prognostic significance of sentinel lymph node status in thick primary melanomas (> 4 mm)","volume":"30","author":"Holmberg","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2025.01.005_bib31","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1245\/s10434-020-08706-0","article-title":"Sentinel lymph node biopsy is prognostic in thickest melanoma cases and should Be performed for thick melanomas","volume":"28","author":"Han","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"35","key":"10.1016\/j.soc.2025.01.005_bib32","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2013.50.1114","article-title":"Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma","volume":"31","author":"Han","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.soc.2025.01.005_bib33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.soc.2025.01.005_bib34","article-title":"Sentinel lymph node biopsy in melanoma","volume":"351","author":"Bigby","year":"2015","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.soc.2025.01.005_bib35","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/sj.bjc.6605849","article-title":"Melanoma sentinel node biopsy and prediction models for relapse and overall survival","volume":"103","author":"Mitra","year":"2010","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.soc.2025.01.005_bib36","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.annonc.2020.11.015","article-title":"Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor","volume":"32","author":"El Sharouni","year":"2021","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.soc.2025.01.005_bib37","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1200\/JCO.2009.27.1627","article-title":"Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases","volume":"28","author":"Balch","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.soc.2025.01.005_bib38","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41379-021-00835-5","article-title":"The sentinel node invasion level (SNIL) as a prognostic parameter in melanoma","volume":"34","author":"Kretschmer","year":"2021","journal-title":"Mod Pathol"},{"issue":"16","key":"10.1016\/j.soc.2025.01.005_bib39","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2010.31.6760","article-title":"Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria","volume":"29","author":"van der Ploeg","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.soc.2025.01.005_bib40","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.soc.2025.01.005_bib41","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.soc.2025.01.005_bib42","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.soc.2025.01.005_bib43","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.soc.2025.01.005_bib44","article-title":"Role of anti-PD-1 antibodies in advanced melanoma: the era of immunotherapy","volume":"10","author":"Sahni","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.soc.2025.01.005_bib45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"issue":"10","key":"10.1016\/j.soc.2025.01.005_bib46","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3390\/cancers11101618","article-title":"A comprehensive review on MAPK: a promising therapeutic target in cancer","volume":"11","author":"Braicu","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.soc.2025.01.005_bib86","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.soc.2022.07.005","article-title":"Clinical Trials in Melanoma: Margins. Lymph Nodes, Targeted and Immunotherapy","volume":"32","author":"Sharon","year":"2023","journal-title":"Surg Oncol Clin N Am"},{"issue":"18","key":"10.1016\/j.soc.2025.01.005_bib47","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final results for adjuvant Dabrafenib plus Trametinib in stage III melanoma","volume":"391","author":"Long","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.soc.2025.01.005_bib87","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.soc.2025.01.005_bib48","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238","volume":"29","author":"Larkin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.soc.2025.01.005_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325\/KEYNOTE-054 trial","volume":"211","author":"Eggermont","year":"2024","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.soc.2025.01.005_bib50","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat Med"},{"issue":"10336","key":"10.1016\/j.soc.2025.01.005_bib51","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.soc.2025.01.005_bib52","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1245\/ASO.2003.10.001","article-title":"Complications associated with sentinel lymph node biopsy for melanoma","volume":"10","author":"Wrightson","year":"2003","journal-title":"Ann Surg Oncol"},{"issue":"24","key":"10.1016\/j.soc.2025.01.005_bib53","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","article-title":"Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011","volume":"25","author":"Lucci","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.01.005_bib85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/CMR.0b013e3282f2017d","article-title":"Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection","volume":"18","author":"Kretschmer","year":"2008","journal-title":"Melanoma Res"},{"issue":"26","key":"10.1016\/j.soc.2025.01.005_bib54","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.soc.2025.01.005_bib55","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.01.005_bib56","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/jso.26225","article-title":"Sentinel lymph node biopsy is associated with increased cost in higher risk thin melanoma","volume":"123","author":"Aiken","year":"2020","journal-title":"J Surg Oncol"},{"issue":"7","key":"10.1016\/j.soc.2025.01.005_bib57","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1007\/s12325-023-02525-x","article-title":"Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of resected stage IIB or IIC melanoma in the United States","volume":"40","author":"Zhang","year":"2023","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.soc.2025.01.005_bib58","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.soc.2025.01.005_bib59","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9584","article-title":"Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: the phase 3 NADINA trial","author":"Lucas","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.soc.2025.01.005_bib61","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.amjoto.2014.08.009","article-title":"FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients","volume":"35","author":"Ryan","year":"2014","journal-title":"Am J Otolaryngol"},{"issue":"7934","key":"10.1016\/j.soc.2025.01.005_bib62","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.soc.2025.01.005_bib63","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.3390\/ijms23042127","article-title":"Lymphatics in tumor progression and immunomodulation","volume":"23","author":"Li","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.soc.2025.01.005_bib64","doi-asserted-by":"crossref","first-page":"450","DOI":"10.6004\/jnccn.2016.0051","article-title":"Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Coit","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.soc.2025.01.005_bib65","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","article-title":"Nomograms in oncology: more than meets the eye","volume":"16","author":"Balachandran","year":"2015","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.soc.2025.01.005_bib66","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1200\/JCO.19.02362","article-title":"Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the melanoma Institute Australia nomogram","volume":"38","author":"Lo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2025.01.005_bib67","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.19895","article-title":"Predicting sentinel node positivity in patients with melanoma: external validation of a risk-prediction calculator (the Melanoma Institute Australia nomogram) using a large European population-based patient cohort","volume":"185","author":"El Sharouni","year":"2021","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.soc.2025.01.005_bib68","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.bjps.2022.01.017","article-title":"Predicting outcomes from sentinel node biopsy for melanoma in the UK: is the MIA nomogram the answer?","volume":"75","author":"Carter","year":"2022","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"3","key":"10.1016\/j.soc.2025.01.005_bib69","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/jamasurg.2023.6904","article-title":"Population-based validation of the MIA and MSKCC tools for predicting sentinel lymph node status","volume":"159","author":"Olofsson Bagge","year":"2024","journal-title":"JAMA Surg"},{"issue":"7","key":"10.1016\/j.soc.2025.01.005_bib70","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/jso.27231","article-title":"Are the MIA and MSKCC nomograms useful in selecting patients with melanoma for sentinel lymph node biopsy?","volume":"127","author":"Hosein","year":"2023","journal-title":"J Surg Oncol"},{"issue":"8","key":"10.1016\/j.soc.2025.01.005_bib71","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1245\/s10434-024-15456-w","article-title":"Impact of an online risk calculator for sentinel node positivity on management of patients with T1 and T2 melanomas","volume":"31","author":"Winder","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2025.01.005_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113989","article-title":"Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy","volume":"202","author":"K\u00f6tt","year":"2024","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.soc.2025.01.005_bib73","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soc.2025.01.005_bib74","article-title":"Society of surgical oncology consensus statement: assessing the evidence for and utility of gene expression profiling of primary cutaneous melanoma","author":"Bartlett","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.01.005_bib75","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12885-018-4016-3","article-title":"Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients","volume":"18","author":"Zager","year":"2018","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.soc.2025.01.005_bib76","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2217\/fon-2018-0912","article-title":"Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling","volume":"15","author":"Vetto","year":"2019","journal-title":"Future Oncol"},{"issue":"7","key":"10.1016\/j.soc.2025.01.005_bib77","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/ijd.15594","article-title":"Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: a U.S. cohort study","volume":"60","author":"Yousaf","year":"2021","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.soc.2025.01.005_bib78","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/bjd.19499","article-title":"Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma","volume":"184","author":"Mulder","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.soc.2025.01.005_bib79","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41698-022-00321-4","article-title":"Prediction of early-stage melanoma recurrence using clinical and histopathologic features","volume":"6","author":"Wan","year":"2022","journal-title":"npj Precis Oncol"},{"issue":"5","key":"10.1016\/j.soc.2025.01.005_bib80","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1200\/JCO.2009.25.7428","article-title":"Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma","volume":"28","author":"Voit","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.soc.2025.01.005_bib81","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1245\/s10434-006-9046-4","article-title":"Ultrasound-guided fine needle aspiration cytology prior to sentinel lymph node biopsy in melanoma patients","volume":"13","author":"Voit","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.01.005_bib82","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2013.08.023","article-title":"The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients","volume":"50","author":"van der Ploeg","year":"2014","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.soc.2025.01.005_bib83","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ad.2017.06.002","article-title":"Use of lymph node ultrasound prior to sentinel lymph node biopsy in 384 patients with melanoma: a cost-effectiveness analysis","volume":"108","author":"Olmedo","year":"2017","journal-title":"Actas Dermosifiliogr"},{"issue":"30","key":"10.1016\/j.soc.2025.01.005_bib84","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1200\/JCO.2008.19.0033","article-title":"Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma?","volume":"27","author":"Voit","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:22:12Z","timestamp":1747941732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320725000055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1055320725000055"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2025.01.005","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nodal Management in Melanoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2025.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}